Vaccines for Acinetobacter baumannii: Thinking "out of the box"

Vaccine

Volumn 32, Issue 22, 2014, Pages 2537-2539

  Perez, Federico ^a   Bonomo, Robert A ^a  

^a LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

Acinetobacter; Immunocompromised; Vaccine

Indexed keywords

ACINETOBACTER BAUMANNII VACCINE; BACTERIAL VACCINE; INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; BIOFILM; CELLULAR IMMUNITY; HUMAN; IMMUNOSURVEILLANCE; INFECTION; INFECTION CONTROL; LONG TERM CARE; MULTIDRUG RESISTANCE; NONHUMAN; NOTE; OUTER MEMBRANE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ACINETOBACTER; IMMUNOCOMPROMISED; VACCINE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; BACTERIAL VACCINES; HUMANS;

EID: 84898543228     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.03.031     Document Type: Note

References (27)

1. Munoz-Price L.S., Weinstein R.A. Acinetobacter infection. N Engl J Med 2008, 358(12):1271-1281.
2. Wright M.S., Haft D.H., Harkins D.M., et al. New insights into dissemination and variation of the health care-associated pathogen Acinetobacter baumannii from genomic analysis. MBio 2014, 5(1):e00913-e00963.
3. Peleg A.Y., de Breij A., Adams M.D., et al. The success of Acinetobacter species; genetic, metabolic and virulence attributes. PLoS One 2012, 7(10):e46984.
4. Adams M.D., Goglin K., Molyneaux N., et al. Comparative genome sequence analysis of multidrug-resistant Acinetobacter baumannii. J Bacteriol 2008, 190(24):8053-8064.
5. Joice R., Lipsitch M. Targeting imperfect vaccines against drug-resistance determinants: a strategy for countering the rise of drug resistance. PLoS One 2013, 8(7):e68940.
6. Weinberger B., Herndler-Brandstetter D., Schwanninger A., Weiskopf D., Grubeck-Loebenstein B. Biology of immune responses to vaccines in elderly persons. Clin Infect Dis 2008, 46(7):1078-1084.
7. Dorrington M.G., Bowdish D.M. Immunosenescence and novel vaccination strategies for the elderly. Front Immunol 2013, 4:171.
8. Falsey A.R., Treanor J.J., Tornieporth N., Capellan J., Gorse G.J. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009, 200(2):172-180.
9. Lode H., Schmoele-Thoma B., Gruber W., et al. Dose-ranging study of a single injection of pneumococcal conjugate vaccine (1×, 2×, or 4×) in healthy subjects aged 70 years or older. Vaccine 2011, 29(31):4940-4946.
10. Duthie M.S., Windish H.P., Fox C.B., Reed S.G. Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev 2011, 239(1):178-196.
11. Xiao W., Mindrinos M.N., Seok J., et al. A genomic storm in critically injured humans. J Exp Med 2011, 208(13):2581-2590.
12. Marik P.E., Flemmer M. The immune response to surgery and trauma: implications for treatment. J Trauma Acute Care Surg 2012, 73(4):801-808.
13. van Faassen H., KuoLee R., Harris G., Zhao X., Conlan J.W., Chen W. Neutrophils play an important role in host resistance to respiratory infection with Acinetobacter baumannii in mice. Infect Immun 2007, 75(12):5597-5608.
14. Qiu H., KuoLee R., Harris G., Van Rooijen N., Patel G.B., Chen W. Role of macrophages in early host resistance to respiratory Acinetobacter baumannii infection. PLoS One 2012, 7(6):e40019.
15. Fowler V.G., Allen K.B., Moreira E.D., et al. Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. JAMA 2013, 309(13):1368-1378.
16. Morens D.M., Burke D.S., Halstead S.B. The wages of original antigenic sin. Emerg Infect Dis 2010, 16(6):1023-1024.
17. Wertheim H.F., Vos M.C., Ott A., et al. Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet 2004, 364(9435):703-705.
18. United States Centers for Disease Control and Prevention Antibiotic resistance threats in the United States, 2013 2013, http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf.
19. Spellberg B., Rex J.H. The value of single-pathogen antibacterial agents. Nat Rev Drug Discovery 2013, 12(12):963.
20. Regnier S.A., Huels J. Drug versus vaccine investment: a modelled comparison of economic incentives. Cost Eff Resour Alloc 2013, 11(1):23.
21. Maragakis L.L., Tucker M.G., Miller R.G., Carroll K.C., Perl T.M. Incidence and prevalence of multidrug-resistant Acinetobacter using targeted active surveillance cultures. JAMA 2008, 299(21):2513-2514.
22. Thom K.A., Maragakis L.L., Richards K., et al. Assessing the burden of Acinetobacter baumannii in Maryland: a statewide cross-sectional period prevalence survey. Infect Control Hosp Epidemiol 2012, 33(9):883-888.
23. Perez F., Hujer A.M., Hujer K.M., Decker B.K., Rather P.N., Bonomo R.A. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007, 51(10):3471-3484.
24. Brady R.A., O'May G.A., Leid J.G., Prior M.L., Costerton J.W., Shirtliff M.E. Resolution of Staphylococcus aureus biofilm infection using vaccination and antibiotic treatment. Infect Immun 2011, 79(4):1797-1803.
25. Casadevall A., Dadachova E., Pirofski L.A. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2004, 2(9):695-703.
26. Moriel D.G., Beatson S.A., Wurpel D.J., et al. Identification of novel vaccine candidates against multidrug-resistant Acinetobacter baumannii. PLoS One 2013, 8(10):e77631.
27. Lin L., Tan B., Pantapalangkoor P., et al. Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis. MBio 2012, 3(5).